Fig. 2.

(A) Change in Itch numerical rating scale (NRS) scores, and (B) the proportions of patients achieving Itch NRS minimal clinically important difference (MCID) (≥ 4 improvement) or (C) Itch NRS (0) when treated with ixekizumab or ustekinumab for 52 weeks. Achievement of Itch NRS MCID was investigated in patients who had Itch NRS scores ≥ 4 at baseline. Itch NRS scores and proportion of patients achieving Itch NRS MCID previously reported for weeks 0–24 (12) *p < 0.05, **p < 0.01, ***p < 0.001, all vs UST by (A) Wilcoxon rank sum or (B & C) Fisher’s exact test. mBOCF: modified baseline-observation carried forward; NRI: non-responder imputation.